{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/vitiligo/diagnosis/assessment/","result":{"pageContext":{"chapter":{"id":"ebc547bc-2b3a-55f8-a703-fff4f5d4f309","slug":"assessment","fullItemName":"Assessment","depth":2,"htmlHeader":"<!-- begin field 938ca46c-02a9-469e-960a-ab9901167b7d --><h2>How should I assess a person with suspected vitiligo?</h2><!-- end field 938ca46c-02a9-469e-960a-ab9901167b7d -->","summary":"","htmlStringContent":"<!-- begin item 67fe88e5-d8e1-4b1d-bdfa-ab9901167b16 --><!-- begin field ff67f4c7-bc7d-4e49-aade-ab9901167b7d --><p><strong>If a person has a <a class=\"topic-reference internal-reference\" href=\"/topics/vitiligo/diagnosis/diagnosis/\">suspected</a> diagnosis of vitiligo, determine whether it is <a class=\"topic-reference internal-reference\" href=\"/topics/vitiligo/background-information/definition/\">non-segmental</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/vitiligo/background-information/definition/\">segmental</a> following clinical examination.</strong></p><ul><li><strong>Ask about:</strong><ul><li>The extent and duration of lesions, lesion activity and spread, and rate of progression or regression of lesions.</li><li>The impact on the person's quality of life, psychosocial issues, or other <a class=\"topic-reference internal-reference\" href=\"/topics/vitiligo/background-information/complications/\">complications</a>. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> and <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> for more information.</li><li>The person's skin type (skin colour and ability to tan), which may affect treatment options. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/vitiligo/diagnosis/assessment/#skin-type-classification\">Skin type classification</a> for more information.</li><li>Any known <a class=\"topic-reference internal-reference\" href=\"/topics/vitiligo/background-information/causes/\">triggers</a> including occupational history/exposure to chemicals.</li><li>Any known <a class=\"topic-reference internal-reference\" href=\"/topics/vitiligo/background-information/risk-factors/\">risk factors</a>, such as family history, or personal or family history of autoimmune disease, which may accompany non-segmental vitiligo.</li><li>Any previous episodes of spontaneous repigmentation, previous treatments and their effectiveness.</li></ul></li><li><strong>Examine the person for:</strong><ul><li>The <a class=\"topic-reference internal-reference\" href=\"/topics/vitiligo/background-information/definition/\">distribution</a> and extent of lesions and any mucosal involvement.</li><li>The presence of <a class=\"topic-reference internal-reference\" href=\"/topics/vitiligo/diagnosis/diagnosis/\">Koebner's phenomenon</a>, confetti-like depigmentation, poorly defined or inflamed borders of lesions, <a class=\"topic-reference internal-reference\" href=\"/topics/vitiligo/diagnosis/diagnosis/\">trichome vitiligo</a>, or depigmented hairs, which may suggest more active disease.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/vitiligo/diagnosis/assessment/#skin-type-classification\">Skin type</a> (skin colour and ability to tan).</li><li>The estimated percentage of body surface area affected in adults using Wallace's 'Rule of Nines' (may overestimate the area affected):<ul><li>Posterior trunk — 18%.</li><li>Anterior trunk — 18%.</li><li>Leg — 18%.</li><li>Neck — 1%.</li><li>Head — 9%.</li><li>Arm — 9%.</li></ul></li><li>Alternatively, the estimated percentage of body surface area affected using a <a href=\"https://www.wounds-uk.com/journals/issue/11/article-details/a-critical-evaluation-of-the-lund-and-browder-chart-1\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"521d829c-744d-4338-8788-aba0010459de\">Lund and Browder chart</a> (this is more accurate, and can be used in adults and children).</li></ul></li><li><strong>Consider arranging blood tests for co-morbid <a class=\"topic-reference internal-reference\" href=\"/topics/vitiligo/background-information/risk-factors/\">autoimmune disease</a> if a diagnosis of non-segmental vitiligo is suspected, such as:</strong><ul><li>Thyroid function tests and thyroid autoantibodies. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information.</li><li>Note: checking autoantibodies for other autoimmune conditions is only recommended if the person's history, family history, and/or other test results are suggestive.</li></ul></li></ul><!-- end field ff67f4c7-bc7d-4e49-aade-ab9901167b7d --><!-- end item 67fe88e5-d8e1-4b1d-bdfa-ab9901167b16 -->","topic":{"id":"72501cc1-fbf6-5c3a-bfc1-1a2d865f7dff","topicId":"85a32b0f-cf7a-41c9-9dd8-caed21004663","topicName":"Vitiligo","slug":"vitiligo","lastRevised":"Last revised in April 2020","chapters":[{"id":"237f05d1-6751-5abf-98b0-af49db55e1b3","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e51e2938-3e89-53a6-9251-b0376a90be4d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"5c590af0-29e5-5be3-958d-02f67350d529","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"aee2331c-c78c-5c0d-ba9a-c974cfb039ae","slug":"changes","fullItemName":"Changes"},{"id":"8afc6e46-c250-5eb3-85a1-355d3e18ee65","slug":"update","fullItemName":"Update"}]},{"id":"78bbc5cd-9e73-55fb-b421-d718417be14a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1a4f8e76-7634-54ba-8849-3051a448dccc","slug":"goals","fullItemName":"Goals"},{"id":"65dbcf54-b53e-54e8-a2fe-a07b8aae49f2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ba868062-b333-5694-90cb-1b24ed0d9c11","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1912341a-6cf7-5d2a-b20d-cb4f55308c36","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"05992da2-cc78-5880-8307-5a5f8e4cc4da","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"30dc5858-bfd0-5918-b331-9067d9743f12","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"33d1fc44-e925-5b20-982d-7e60d75465ea","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c23ed46f-6f85-51ef-9f34-aea63f9aea9e","slug":"definition","fullItemName":"Definition"},{"id":"cfca1785-6f25-546b-8fba-a9bb5ec8bc4f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1c68db6d-01f9-5407-b229-ad9ba72d53b1","slug":"causes","fullItemName":"Causes"},{"id":"def00a0c-fcf5-5066-b8b6-d4197121b345","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4b6c885f-0d2d-5b2c-abeb-495372e63081","slug":"complications","fullItemName":"Complications"},{"id":"63ac95a4-7b80-5aef-bf7b-cc1b8b812a1c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9b1dd44e-152a-5b47-8bbd-a07a6000032f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"465324e6-d6e2-5263-8c5d-9368e36b2d89","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ebc547bc-2b3a-55f8-a703-fff4f5d4f309","slug":"assessment","fullItemName":"Assessment"},{"id":"dea3c9af-e347-5a61-8a6e-852afbca1f6b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"674a723c-f8af-5b44-b6fc-6d46ad281431","fullItemName":"Management","slug":"management","subChapters":[{"id":"d85da703-7350-5165-a4eb-3697e45db487","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"8ddf3c8a-0168-521b-a940-e841ebe05935","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0f441642-e226-5709-89d2-b4f6eeee7a85","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d538aa6d-327c-503c-b574-69a24bbfd9f0","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c5bed09a-eccb-5abe-8ff1-63f178d8c28c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f56b39ed-360e-5ae6-9103-c21bb5e9862d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ba61933a-4f62-5bb3-988b-9749f78e6265","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"31c2bb80-d9f1-5095-b859-2ad42da47934","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a43f071b-fb92-55e3-a42d-348c5fd48924","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9b1dd44e-152a-5b47-8bbd-a07a6000032f","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"29c9f67a-389b-508a-807f-607bf62bd5b1","slug":"skin-type-classification","fullItemName":"Skin type classification","depth":3,"htmlHeader":"<!-- begin field 1a78b1e1-729f-41ee-998a-ab9901174075 --><h3>Skin type classification</h3><!-- end field 1a78b1e1-729f-41ee-998a-ab9901174075 -->","summary":null,"htmlStringContent":"<!-- begin item ef99f9c7-a44a-4245-81ac-ab9901174052 --><!-- begin field ee87fd1d-b4b8-486e-bea4-ab9901174075 --><p>The information in Table 1 provides a classification of skin type according to skin colour and ability to tan.</p><p><strong>Table 1.</strong> Fitzpatrick skin type</p><table data-table-id=\"c1a90de1-4d1b-4123-822b-acce014c977c\"><thead><tr><th scope=\"col\">Skin type</th><th scope=\"col\">Typical features</th><th scope=\"col\">Tanning ability</th></tr></thead><tbody><tr><td>I</td><td>Pale white skin, blue/hazel eyes, blonde/red hair</td><td>Always burns, does not tan</td></tr><tr><td>II</td><td>Fair skin, blue eyes</td><td>Burns easily, tans poorly</td></tr><tr><td>III</td><td>Darker white skin</td><td>Tans after initial burn</td></tr><tr><td>IV</td><td>Lighter brown skin</td><td>Burns minimally, tans easily</td></tr><tr><td>V</td><td>Brown skin</td><td>Rarely burns, tans darkly easily</td></tr><tr><td>VI</td><td>Dark brown or black skin</td><td>Never burns, always tans darkly</td></tr><tr><td colspan=\"3\">Data from [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Fitzpatrick, 1988</a>]</td></tr></tbody></table><!-- end field ee87fd1d-b4b8-486e-bea4-ab9901174075 --><!-- end item ef99f9c7-a44a-4245-81ac-ab9901174052 -->","subChapters":[]},{"id":"dd202fde-af14-58e8-9419-b5848fc68a4c","slug":"basis-for-recommendation-b5c","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 9156ddb3-083b-46b3-974b-ab9901167b8e --><h3>Basis for recommendation</h3><!-- end field 9156ddb3-083b-46b3-974b-ab9901167b8e -->","summary":null,"htmlStringContent":"<!-- begin item b5cfc868-0b5e-47b2-b4be-ab9901167b8e --><!-- begin field 4c9bb584-6a82-4d4d-aae6-ab9901167b8e --><p>The recommendations on assessment are largely based on the British Association of Dermatologists (BAD) publication <em>Guideline for the diagnosis and management of vitiligo</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Gawkrodger, 2008</a>]; the Vitiligo European Task Force (VETF) consensus documents <em>The definition and assessment of vitiligo</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Taieb, 2007</a>] and <em>Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Ezzedine, 2012</a>]; the European Dermatology Forum consensus document <em>Guidelines for the management of vitiligo</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Taieb, 2013</a>]; a cross-sectional study on autoimmune disease in people with vitiligo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Gill, 2016</a>]; a systematic review of the prevalence of psychological co-morbidity in people with vitiligo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Osinubi, 2017</a>]; a systematic review of quality of life in people with vitiligo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Morrison, 2017</a>]; a meta-analysis of clinical signs of active disease in vitiligo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">van Geel, 2019</a>]; and expert opinion in review articles on vitiligo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Ezzedine, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Goh, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Bergqvist, 2020</a>], on vitiligo in children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Ezzedine, 2016</a>], on hypopigmentation disorders [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Hill, 2017</a>], and in a chapter in a medical textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Gupta and Ramam, 2014</a>].</p><h4>Clinical features on history taking</h4><ul><li>The recommendation to differentiate between segmental and non-segmental vitiligo is important because these subtypes differ in terms of prognosis, natural history, and response to treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Ezzedine, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Ezzedine, 2016</a>].</li><li>The recommendations on the clinical features in the history to assess for people with suspected vitiligo are based on the VETF consensus document [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Taieb, 2007</a>], the European Dermatology Forum consensus document [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Taieb, 2013</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Ezzedine, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Bergqvist, 2020</a>].</li><li>The importance of assessing psychosocial issues and impact on quality of life is highlighted in the BAD guideline publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Gawkrodger, 2008</a>], the European Dermatology Forum consensus document [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Taieb, 2013</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Ezzedine, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Hill, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Bergqvist, 2020</a>].</li><li>The recommendation to assess for risk factors including occupational history/exposure to chemicals is based on the European Dermatology Forum consensus document [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Taieb, 2013</a>] and is also extrapolated from expert opinion in a review article, as a positive occupational history may suggest a differential diagnosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Bergqvist, 2020</a>].</li><li>The recommendation to assess for a history of co-existing autoimmune disorders is based on the BAD guideline publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Gawkrodger, 2008</a>], the European Dermatology Forum consensus document [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Taieb, 2013</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Ezzedine, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Ezzedine, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Bergqvist, 2020</a>].</li></ul><h4>Clinical features on examination</h4><ul><li>The BAD guideline publication notes that a full skin examination is important to assess disease severity and individual prognostic factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Gawkrodger, 2008</a>]. This approach is supported by expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Bergqvist, 2020</a>].</li><li>The information on the clinical features that may suggest more active disease is based on a meta-analysis of clinical signs of active disease in vitiligo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">van Geel, 2019</a>], the European Dermatology Forum consensus document [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Taieb, 2013</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Goh, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Bergqvist, 2020</a>].<ul><li>Signs of active disease may indicate prognosis and can affect specialist treatment choices [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Goh, 2017</a>].</li><li>The presence of Koebner’s phenomenon represents a clinical marker of active, progressive disease, and measures to avoid mechanical trauma in such people may help in the prevention of vitiligo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Taieb, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Bergqvist, 2020</a>].</li></ul></li><li>The recommendation to assess the person's skin type is based on the BAD guideline publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Gawkrodger, 2008</a>].</li><li>The recommendation to assess the extent of disease using the 'Rule of Nines' is based on the VETF consensus document [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Taieb, 2007</a>] and expert opinion in a medical textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Gupta and Ramam, 2014</a>]. The recommendation to consider alternative use of a Lund and Browder chart is pragmatic, based on what CKS considers to be sensible clinical practice.</li></ul><h4>Arranging blood tests for co-existing autoimmune disease</h4><ul><li>The information on when to consider arranging blood tests for co-existing autoimmune disease is based on the fact there is an increased prevalence of autoimmune thyroid and other disease in people with non-segmental vitiligo compared with the general population [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Gawkrodger, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Taieb, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Ezzedine, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Ezzedine, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Bergqvist, 2020</a>].<ul><li>A US cross-sectional cohort study on autoimmune disease in people with vitiligo (n = 1098) found nearly 20% of people had at least one co-morbid autoimmune disease, and rates were higher than in the general population. The authors noted, however, there was no control group included in the study, and there was potential selection bias as the study was conducted in a single institution setting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Gill, 2016</a>].</li></ul></li></ul><!-- end field 4c9bb584-6a82-4d4d-aae6-ab9901167b8e --><!-- end item b5cfc868-0b5e-47b2-b4be-ab9901167b8e -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}